晚期胰腺癌靶向治疗与免疫治疗的进展  

Advances in targeted therapy and immunotherapy for advanced pancreatic cancer

作　　者：郭舜尧 孔超 周易 于苏川 陆海艳 肖辛瑶 沈华 GUO Shunyao;KONG Chao;ZHOU Yi;YU Suchuan;LU Haiyan;XIAO Xinyao;SHEN Hua(Department of Oncology,Sir Run Run Hospital Nanjing Medical University,Nanjing,Jiangsu 211100,China)

机构地区：[1]南京医科大学附属逸夫医院肿瘤科,江苏南京211100

出　　处：《中国临床研究》2025年第3期483-487,共5页Chinese Journal of Clinical Research

摘　　要：胰腺癌是一种侵袭性极强且预后极差的恶性肿瘤,现有的治疗方案疗效有限。近年来,随着分子靶向治疗、免疫治疗等新兴治疗手段的发展,胰腺癌的治疗取得了一些进展。本综述重点探讨了几种前沿的治疗策略,包括针对KRAS突变的靶向治疗、DNA损伤修复通路的抑制、免疫检查点抑制剂的应用以及嵌合抗原受体T细胞免疫疗法(CAR-T)在胰腺癌中的前景。此外,文章分析了胰腺癌肿瘤微环境的免疫抑制特征,讨论了新兴治疗手段如抗血管生成药物、代谢治疗和肿瘤疫苗的潜力。Pancreatic cancer is a highly aggressive malignancy with a poor prognosis,and current therapies show limited efficacy.In recent years,with the development of emerging therapies such as molecular targeted therapy and immunotherapy,some progress has been made in the treatment of pancreatic cancer.This review focuses on several cutting-edge therapeutic strategies,including targeted therapies against KRAS mutations,inhibition of DNA damage repair pathways,the application of immune checkpoint inhibitors,and the potential of CAR-T cell therapy in pancreatic cancer.Additionally,the article analyzes the immunosuppressive characteristics of the tumor microenvironment in pancreatic cancer and discusses the potential of emerging treatments such as anti-angiogenic drugs,metabolic therapy,and cancer vaccines.

关 键 词：胰腺导管腺癌 靶向治疗 免疫治疗 KRAS突变 肿瘤微环境 

分 类 号：R735.9[医药卫生—肿瘤]